Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Kartos Therapeutics

Tracked across 3 events · 20 articles · First seen Apr 20, 2026 · Last active Aug 21, 2026

Sentiment
53
Attention
6
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 80
Business
Impact: Kartos Therapeutics is being acquired by Ipsen for up to $1.75 billion, including an upfront payment and potential milestone payments. Its primary asset, navtemadlin, will be integrated into Ipsen's pipeline.
Apr 20, 2026 · 7 articles
4 80
Business
Ipsen announced on 21 August 2026 that it has completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company. The acquisition adds navtemadlin, a late-stage MDM2 inhibitor in Phase III development for myelofibrosis, to Ipsen's…
Impact: Kartos Therapeutics was acquired by Ipsen, providing shareholders with a $450 million upfront payment and potential milestones. The acquisition validates its lead asset navtemadlin.
Aug 21, 2026 · 7 articles
1 0
Business
Impact: Kartos Therapeutics is mentioned as a current board seat for Borellini; not directly affected by this event.
Jul 13, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Kartos Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.